Jonathan Warren Waks, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrocardiography | 23 | 2023 | 6442 | 3.170 |
Why?
|
| Death, Sudden, Cardiac | 11 | 2023 | 1541 | 2.800 |
Why?
|
| Tachycardia, Ventricular | 8 | 2023 | 1273 | 1.780 |
Why?
|
| Defibrillators, Implantable | 10 | 2021 | 1440 | 1.770 |
Why?
|
| Vectorcardiography | 4 | 2023 | 43 | 1.750 |
Why?
|
| Atrial Fibrillation | 17 | 2023 | 5034 | 1.070 |
Why?
|
| Arrhythmias, Cardiac | 6 | 2023 | 2268 | 0.930 |
Why?
|
| Catheter Ablation | 9 | 2023 | 2758 | 0.860 |
Why?
|
| Quinidine | 2 | 2019 | 57 | 0.840 |
Why?
|
| Heart Failure, Systolic | 2 | 2021 | 126 | 0.840 |
Why?
|
| Phenethylamines | 2 | 2019 | 96 | 0.830 |
Why?
|
| Heart Ventricles | 6 | 2023 | 3821 | 0.820 |
Why?
|
| Heart Rate | 6 | 2023 | 4091 | 0.810 |
Why?
|
| Heart Conduction System | 3 | 2016 | 1047 | 0.760 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2020 | 789 | 0.710 |
Why?
|
| Torsades de Pointes | 1 | 2020 | 78 | 0.690 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2018 | 2073 | 0.680 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 1738 | 0.670 |
Why?
|
| Risk Assessment | 14 | 2021 | 23338 | 0.600 |
Why?
|
| Telemetry | 1 | 2018 | 205 | 0.580 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 6 | 2023 | 493 | 0.570 |
Why?
|
| Warfarin | 2 | 2015 | 1496 | 0.540 |
Why?
|
| Tachycardia | 2 | 2015 | 619 | 0.540 |
Why?
|
| Anticoagulants | 6 | 2018 | 4599 | 0.540 |
Why?
|
| Primary Prevention | 2 | 2021 | 1167 | 0.530 |
Why?
|
| Pacemaker, Artificial | 2 | 2018 | 816 | 0.500 |
Why?
|
| Body Surface Potential Mapping | 1 | 2016 | 238 | 0.500 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2018 | 531 | 0.490 |
Why?
|
| Myocardial Infarction | 5 | 2018 | 11727 | 0.480 |
Why?
|
| Thromboembolism | 3 | 2014 | 986 | 0.450 |
Why?
|
| Tachycardia, Supraventricular | 3 | 2023 | 263 | 0.440 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 684 | 0.430 |
Why?
|
| Myocardial Reperfusion | 1 | 2014 | 351 | 0.420 |
Why?
|
| Sulfonamides | 2 | 2019 | 1938 | 0.420 |
Why?
|
| Ventricular Fibrillation | 1 | 2015 | 538 | 0.410 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2015 | 845 | 0.400 |
Why?
|
| Atrial Appendage | 1 | 2015 | 283 | 0.390 |
Why?
|
| Antithrombins | 1 | 2013 | 304 | 0.380 |
Why?
|
| Heart Failure | 8 | 2019 | 10900 | 0.370 |
Why?
|
| Pulmonary Embolism | 1 | 2023 | 2376 | 0.360 |
Why?
|
| Benzimidazoles | 1 | 2013 | 850 | 0.320 |
Why?
|
| Cause of Death | 2 | 2016 | 3584 | 0.310 |
Why?
|
| Algorithms | 6 | 2023 | 13881 | 0.300 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 15165 | 0.300 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2170 | 0.290 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1786 | 0.290 |
Why?
|
| Stroke | 4 | 2018 | 9981 | 0.290 |
Why?
|
| Electric Countershock | 3 | 2018 | 534 | 0.260 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2023 | 719 | 0.250 |
Why?
|
| High-Frequency Jet Ventilation | 1 | 2023 | 23 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2538 | 0.230 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2023 | 66 | 0.230 |
Why?
|
| Atrial Flutter | 2 | 2015 | 263 | 0.220 |
Why?
|
| Humans | 48 | 2023 | 744343 | 0.210 |
Why?
|
| Reproducibility of Results | 7 | 2023 | 19905 | 0.210 |
Why?
|
| Device Removal | 2 | 2018 | 656 | 0.210 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2015 | 585 | 0.200 |
Why?
|
| Pyridines | 1 | 2013 | 2825 | 0.200 |
Why?
|
| Male | 30 | 2023 | 350118 | 0.200 |
Why?
|
| Action Potentials | 3 | 2018 | 1806 | 0.200 |
Why?
|
| Survival Analysis | 3 | 2021 | 10252 | 0.200 |
Why?
|
| Aged | 22 | 2023 | 163280 | 0.190 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 1585 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 3068 | 0.190 |
Why?
|
| Female | 31 | 2023 | 380194 | 0.190 |
Why?
|
| Sodium Channel Blockers | 2 | 2019 | 176 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 10943 | 0.190 |
Why?
|
| Pulmonary Veins | 2 | 2017 | 761 | 0.190 |
Why?
|
| Models, Cardiovascular | 2 | 2016 | 996 | 0.180 |
Why?
|
| Middle Aged | 22 | 2023 | 213383 | 0.170 |
Why?
|
| Potassium Channel Blockers | 1 | 2019 | 171 | 0.170 |
Why?
|
| Incidence | 7 | 2020 | 20947 | 0.170 |
Why?
|
| Risk Factors | 14 | 2021 | 72290 | 0.160 |
Why?
|
| Software | 2 | 2023 | 4443 | 0.160 |
Why?
|
| Stroke Volume | 4 | 2018 | 5007 | 0.160 |
Why?
|
| Hypotension | 1 | 2023 | 884 | 0.150 |
Why?
|
| Patient Selection | 3 | 2018 | 4215 | 0.150 |
Why?
|
| Treatment Outcome | 15 | 2022 | 63114 | 0.150 |
Why?
|
| Ventricular Premature Complexes | 1 | 2018 | 111 | 0.140 |
Why?
|
| Heart Atria | 2 | 2023 | 1357 | 0.140 |
Why?
|
| Retrospective Studies | 11 | 2023 | 77449 | 0.130 |
Why?
|
| Prognosis | 5 | 2023 | 29063 | 0.130 |
Why?
|
| Linear Models | 2 | 2016 | 5952 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6487 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2029 | 0.120 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2015 | 124 | 0.120 |
Why?
|
| Drug Tolerance | 1 | 2015 | 376 | 0.120 |
Why?
|
| Bradycardia | 1 | 2015 | 307 | 0.120 |
Why?
|
| Myocardial Revascularization | 1 | 2018 | 841 | 0.120 |
Why?
|
| Time Factors | 8 | 2018 | 40075 | 0.110 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2014 | 214 | 0.110 |
Why?
|
| Acetanilides | 1 | 2014 | 168 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12354 | 0.110 |
Why?
|
| Survival Rate | 4 | 2021 | 12788 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 14722 | 0.110 |
Why?
|
| Half-Life | 1 | 2013 | 661 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2022 | 5078 | 0.110 |
Why?
|
| Causality | 2 | 2016 | 1275 | 0.110 |
Why?
|
| Sex Factors | 3 | 2015 | 10397 | 0.100 |
Why?
|
| Acute Disease | 1 | 2023 | 7149 | 0.100 |
Why?
|
| Syncope | 1 | 2015 | 429 | 0.100 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 39050 | 0.100 |
Why?
|
| Atherosclerosis | 2 | 2018 | 3445 | 0.100 |
Why?
|
| Recurrence | 3 | 2018 | 8340 | 0.100 |
Why?
|
| Electrodes, Implanted | 1 | 2015 | 824 | 0.100 |
Why?
|
| Ventricular Function, Left | 3 | 2018 | 3670 | 0.100 |
Why?
|
| United States | 7 | 2021 | 69872 | 0.100 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2018 | 1534 | 0.090 |
Why?
|
| Coronary Thrombosis | 1 | 2014 | 495 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 1018 | 0.090 |
Why?
|
| Prospective Studies | 8 | 2023 | 53288 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 841 | 0.090 |
Why?
|
| Comorbidity | 4 | 2018 | 10388 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2019 | 1859 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2015 | 3913 | 0.090 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 57776 | 0.080 |
Why?
|
| Syndrome | 1 | 2015 | 3251 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 6489 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2014 | 899 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 12245 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2018 | 8324 | 0.080 |
Why?
|
| Coronary Circulation | 1 | 2014 | 1572 | 0.080 |
Why?
|
| Epilepsy | 1 | 2023 | 3310 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2759 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 2148 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2022 | 3461 | 0.070 |
Why?
|
| Artifacts | 1 | 2015 | 1904 | 0.070 |
Why?
|
| Minnesota | 2 | 2018 | 344 | 0.070 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 1912 | 0.070 |
Why?
|
| Haemophilus influenzae | 1 | 2006 | 171 | 0.070 |
Why?
|
| Neuraminidase | 1 | 2006 | 210 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12026 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2018 | 40561 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 1813 | 0.060 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2219 | 0.060 |
Why?
|
| Piperazines | 1 | 2014 | 2488 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 15076 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2020 | 21746 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2013 | 2149 | 0.050 |
Why?
|
| Bed Rest | 1 | 2022 | 84 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2014 | 4577 | 0.050 |
Why?
|
| Biofilms | 1 | 2006 | 617 | 0.050 |
Why?
|
| Aspirin | 1 | 2014 | 3282 | 0.050 |
Why?
|
| Acute Coronary Syndrome | 1 | 2014 | 2337 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7279 | 0.050 |
Why?
|
| Boston | 3 | 2018 | 9313 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 3508 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2023 | 924 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 12261 | 0.040 |
Why?
|
| Adult | 6 | 2019 | 214055 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2006 | 1219 | 0.040 |
Why?
|
| Belgium | 1 | 2018 | 103 | 0.040 |
Why?
|
| Massachusetts | 3 | 2016 | 8663 | 0.040 |
Why?
|
| Age Factors | 1 | 2015 | 18370 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 610 | 0.040 |
Why?
|
| Recovery of Function | 2 | 2018 | 2925 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 9959 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6538 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2023 | 7729 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2006 | 3036 | 0.030 |
Why?
|
| Registries | 2 | 2023 | 8089 | 0.030 |
Why?
|
| Electric Power Supplies | 1 | 2015 | 99 | 0.030 |
Why?
|
| Hospitalization | 1 | 2014 | 10262 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2015 | 623 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2018 | 1206 | 0.030 |
Why?
|
| North America | 1 | 2016 | 1249 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2015 | 578 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 414 | 0.030 |
Why?
|
| Diuretics | 1 | 2015 | 592 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2018 | 1184 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2014 | 502 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3952 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2022 | 3313 | 0.020 |
Why?
|
| Animals | 3 | 2018 | 168757 | 0.020 |
Why?
|
| Prevalence | 2 | 2016 | 15226 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2014 | 956 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2018 | 2575 | 0.020 |
Why?
|
| Age Distribution | 1 | 2014 | 2902 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 15540 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 6895 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 3582 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 4933 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 3674 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 5319 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 5102 | 0.020 |
Why?
|
| Health Status | 1 | 2018 | 4034 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2006 | 316 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9849 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2016 | 6196 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3610 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2015 | 3114 | 0.010 |
Why?
|
| Disease Progression | 1 | 2018 | 13284 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2016 | 5102 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2006 | 1539 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 12959 | 0.010 |
Why?
|
| Logistic Models | 1 | 2015 | 13408 | 0.010 |
Why?
|
| Phenotype | 1 | 2018 | 16365 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2006 | 2751 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 13989 | 0.010 |
Why?
|
| Quality of Life | 1 | 2018 | 12804 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25043 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 13815 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 18111 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3848 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 18029 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 81183 | 0.000 |
Why?
|